PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Scientists sequence genome of high-value grape, seek secrets of wine's aroma

Marking 25th year, UNU-BIOLAC also announces brokered breakthrough to diagnose widespread problem of syphilis with a quick, $1 test

2013-09-02
(Press-News.org) Demystifying the chemical processes that create a wine's aroma, and the invaluable potential application of that understanding in winemaking, is the new objective of scientists in Uruguay who, with European partners, also recently sequenced the genome of the high-value Tannat grape, from which "the most healthy of red wines" are fermented.

Meanwhile, a quick, $1 test in development by researchers in Paraguay and Uruguay promises to reduce the economic and health burden of 3 million cases of syphilis in Latin America -- a disease readily treated and cured if diagnosed early.

Though seemingly disparate, the twin breakthroughs have a common midwife: the UN University's Venezuela-based BIOLAC programme, which in 2013 marks 25 years of advancing regional economic and health interests by building biotech science throughout Latin America and the Caribbean.

Connected at UNU-BIOLAC workshops in Montevideo, Uruguayan chemistry professor Francisco Carrau and scientist Massimo Delledonne of Italy recently collaborated on sequencing the Tannat grape, pressings of which, thanks partly to its many seeds, produces the largest concentration of tannins -- an anti-oxidant that combats the ageing of cells.

Wines made from the Tannat are known as the most healthy of red wines due to their high levels of procyanidins, said to be good for reducing blood pressure, lowering cholesterol and encouraging healthy blood clotting.

Says Prof. Carrau: "A wine made with Tannat has twice the tannins of Cabernet Sauvignon, Merlot or Pinot Noir. Sequencing the grape's genome will allow vintners to protect a valuable niche in the world's $300 billion wine industry."

Now the same researchers are probing a secret of nature of potentially great commercial interest as well: how soil conditions, minerals, sun, temperature, climate, altitude and other environmental factors affect the expression of genes in grapes and the chemistry of wine's aromas and color.

"Winemaking has always been an art. Today it is also a science," says Prof. Carrau. "If we can determine through biotechnology the factors that determine a wine's aroma and color, we can potentially apply that information to create more pleasing and valuable products."

"Such information can also valuably guide decisions about where to plant new vines, which typically produce their first fruit after five years and their best fruit in about a decade. Having the ability to predict successful vineyard location holds enormous value."

Tannat is the "national grape" of Uruguay, South America's 4th-largest wine producer with 8,500 hectares (21,000 acres) of vineyards. More than a third of the grapes grown are Tannat, from which the country's signature wines are produced.

Plantings of Tannat (also known in Uruguay as Harriague) have been increasing each year as that country's wine industry develops. Though a small player still, Uruguay is a rising star in the world's wine industry, exporting about 17% of its production (over 20 million litres valued at $15 million in 2012; a roughly 500% jump in the value of exports from 2004).

The main exports are Tannat or Tannat blends and vineyards in Uruguay have begun to distinguish between "old vines" -- descendants from the original cuttings brought over from Europe -- and new clones being produced today. The newer vines tend to produce more powerful wines with higher alcohol levels but less acidity, as well as more complex fruit characteristics.

"Discovering in more detail the health-promoting compound in the Tannat grape requires us to continue work on its genome. I suspect that in future, such information will help the variety become far better known around the world."

Breakthrough 2:

A quick, $1 syphilis test to make diagnosis readily available throughout Latin America

Syphilis has become, again, a serious health issue in Latin American countries with 3 million cases. Every year 330,000 pregnant women with syphilis receive no treatment resulting in 110,000 children born with congenital syphilis and a similar number of miscarriages.

"Early diagnosis is essential because to cure syphilis we only need penicillin. It is very cheap, very easy. The sole challenge is to obtain immediate diagnosis," says Monica Marín, Professor of Biochemistry and Molecular Biology at Uruguay's University of the Republic.

Unfortunately, she says, commercial kits for early syphilis detection are too expensive to use in a systematic screening of all pregnancies in Latin American countries where, in some areas, there are five new cases daily.

The proteins needed for the test come from the bacterium that causes syphilis. And reducing the price of the tests requires producing high volumes of these proteins, explains Dr. Marín.

That's where UNU-BIOLAC provided help, supporting two courses in the development of diagnosis methods and recombinant protein production and purification processes.

"BIOLAC was the starting point. Without them, this could not have been possible," says Dr. Marín.

The courses, conducted in Paraguay, were co-organized by Graciela Velazquez and Graciela Russomando of Paraguay and, from Uruguay, Dr. Marin and Mario Señorale. They set a simple problem-based goal: develop a $1 dollar early detection kit that would work as easily as popular pregnancy tests. The syphilis test would be administered together with the pregnancy test in health centers, allowing for immediate point of care administration of penicillin to treat any detected infection.

Says Dr. Marín: "Obtained via DNA technologies used in the training courses, the proteins have proven highly sensitive and specific in detecting syphilis. To mass produce them, we are now using BIOLAC workshops to optimize the genetic expression and purification experimental procedures."

"By next year, we anticipate having ready to use throughout Latin America a diagnostic test of the same quality as those available commercially today but at least 25 times cheaper."

"UNU-BIOLAC provides training and undertakes research at the intersection of science, technology, and society, helping the region employ modern biotechnology in social and economic development," says Jose Luis Ramirez, Director of the UNU-BIOLAC programme since year 2000.

The Programme's priority research areas: Climate change and bioenergy, human health and controlling the vectors of disease, industrial and agricultural biotechnology, art conservation, intellectual property, and technology transfer.

UNU-BIOLAC's work in the use of biotechnology to preserve items of priceless cultural value was highlighted in 2009 (see http://bit.ly/14x36hO). As stated at the time: Entire collections of museums of several tropical countries are compromised by climate change and lack of funding.

Headquartered in Caracas at the campus of the Instituto de Estudios Avanzados beside Simon Bolivar University, Dr. Ramirez says a priority in this field is to halt the slow decay of archives of Bolivar's papers.

"UNU-BIOLAC has played a proud and important role in many proud achievements over the past 25 years, exemplified by such breakthroughs as the genetic sequencing of an increasingly valuable grape and the development of a low-cost test for syphilis -- a common and devastating illness," says Dr. Ramirez.

Says United Nations Under Secretary-General David Malone, Rector of UNU: "The conviction driving the launch of this programme -- that biotechnology science can make a major contribution to the health of the people and economies of Latin America and the Caribbean -- has proved true in so many ways over the past quarter century. We look forward to exploring further new possibilities of great relevance to these regions in years ahead."



INFORMATION:



Background

UNU-BIOLAC, established in Caracas in 1988 with core funding from the Government of Venezuela, is a research and training programme of the United Nations University.

The programme's mission: "To promote the application of biotechnology for the development of Latin American and Caribbean countries, by building capacities and generating new knowledge and conducting focused research to solving constraints which are critical to the region."

One of the three UNU Research and Training Centres / Programmes headquartered in the developing world, UNU-BIOLAC connects academic institutions and researchers throughout the region, promoting workshops, seminars, training courses, lectures and similar academic activities; and by financing training fellowships for young researchers.

In a six-year period, UNU-BIOLAC has designed, promoted and organized the implementation of 61 training courses, involving the participation of 4,512 persons from 13 Latin America and Caribbean countries; 880 fellowships were assigned.

UNU-BIOLAC's work in biosafety and related capacity building is ranked among its most successful, with a direct spin-off in the establishment of a tracking facility for genetically modified organisms in the IDEA (Instituto de Estudios Avanzados), Caracas, using a contribution by the Venezuelan Government.

Among other success stories: development of regional forensic science capabilities and streamlining the genomic sequencing related to local agriculture diseases.

Studies related to tuberculosis and the epidemiology of infectious diseases are among key pursued, along with biosafety, bioinformatics and bioethics, all of great current relevance in Latin America and the Caribbean.

Upcoming UNU-BIOLAC events include, in Ecuador, the 2nd "International Workshop on Molecular Epidemiology of Parasites and Dengue" (Oct 2-5, 2013).



ELSE PRESS RELEASES FROM THIS DATE:

Drug reduces hospitalizations and cost of treating young children with sickle cell anemia

2013-09-02
A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics. The study is the largest ever focusing on the economic impact of the drug hydroxyurea in children with the inherited blood disorder. The result supports expanded use of the drug to extend the length and quality of life for ...

Risk factors for cardiovascular problems found to be inverse to disease and deaths

2013-09-02
Hamilton, ON (September 2, 2013) – Despite living with the highest risk factors for heart disease, people in high income countries suffer less from serious cardiovascular disease, says an international study by the global PURE (Prospective Urban Rural Epidemiology ) collaboration and led by McMaster University researchers. At the same time, the study found that people in low income countries, although living with fewer risk factors for heart disease, have a higher incidence of serious cardiovascular disease including death. "These findings were a total surprise," ...

Metabolically healthy women have same CVD risk regardless of BMI

2013-09-02
Amsterdam, The Netherlands – Monday 2 September 2013: Metabolically healthy women have the same cardiovascular disease risk regardless of their BMI, according to research presented at the ESC Congress today by Dr Søren Skøtt Andersen and Dr Michelle Schmiegelow from Denmark. The findings in more than 260,000 subjects suggest that obese women have a window of opportunity to lose weight and avoid developing a metabolic disorder, which would increase their CVD risk. Dr Schmiegelow said: "Obesity and/or metabolic disorders (hypertensive disorders [hypertension, gestational ...

Pacemaker for slow heart rhythm restores life expectancy

2013-09-02
Amsterdam, The Netherlands – Monday 2 September 2013 : Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients. Dr Udo said: "Previous studies describing the survival of pacemaker patients used data that is more than 20 years old and cannot be used anymore for patient counselling and benchmarking. There have been considerable changes in pacemaker technology ...

ASSURE study of experimental agent to raise HDL yields 'disappointing and surprising' results

2013-09-02
AMSTERDAM, The Netherlands, 2 September2013 – The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study. The lack of efficacy of RVX-208 is "disappointing and surprising, given promising earlier findings," noted lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research ...

Common blood pressure drug reduces aortic enlargement in Marfan syndrome

2013-09-02
AMSTERDAM, The Netherlands - A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome. Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment. "Our study is the first large, prospective randomized study to assess the effects ...

Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS

2013-09-02
AMSTERDAM, The Netherlands – Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress. "Compared with placebo, treatment with alogliptin resulted in similar rates of the primary endpoint, which was a composite of cardiovascular death, myocardial ...

Move it and lose it: Every 'brisk' minute counts

2013-09-01
To win the war against weight gain, it turns out that every skirmish matters – as long as the physical activity puts your heart and lungs to work. In a new study published today in the American Journal of Health Promotion, University of Utah researchers found that even brief episodes of physical activity that exceed a certain level of intensity can have as positive an effect on weight as does the current recommendation of 10 or more minutes at a time. "What we learned is that for preventing weight gain, the intensity of the activity matters more than duration," says ...

Anticoagulant does not reduce rate of ischemic events among certain patients undergoing PCI

2013-09-01
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non–ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013 "Major progress has been made in ...

Big belly increases death risk in heart attack survivors

2013-09-01
Amsterdam, The Netherlands – Sunday 1 September 2013 : Having a big belly increases the risk of death in heart attack survivors, according to research presented at ESC Congress 2013 by Professor Tabassome Simon and Professor Nicolas Danchin from France. The findings from the FAST-MI 2005 registry suggest that lifestyle interventions in heart attack patients should focus on losing abdominal fat. Professor Simon said: "The impact of obesity on long term mortality and cardiovascular complications in the general population has been the object of recent debate. Much emphasis ...

LAST 30 PRESS RELEASES:

Risk of internal bleeding doubles when people on anticoagulants take NSAID painkiller

‘Teen-friendly’ mindfulness therapy aims to help combat depression among teenagers

Innovative risk score accurately calculates which kidney transplant candidates are also at risk for heart attack or stroke, new study finds

Kidney outcomes in transthyretin amyloid cardiomyopathy

Partial cardiac denervation to prevent postoperative atrial fibrillation after coronary artery bypass grafting

Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction

Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction

Hormone therapy reshapes the skeleton in transgender individuals who previously blocked puberty

Evaluating performance and agreement of coronary heart disease polygenic risk scores

Heart failure in zero gravity— external constraint and cardiac hemodynamics

Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden

New study finds air pollution increases inflammation primarily in patients with heart disease

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski

Excessive screen time linked to early puberty and accelerated bone growth

First nationwide study discovers link between delayed puberty in boys and increased hospital visits

Traditional Mayan practices have long promoted unique levels of family harmony. But what effect is globalization having?

New microfluidic device reveals how the shape of a tumour can predict a cancer’s aggressiveness

Speech Accessibility Project partners with The Matthew Foundation, Massachusetts Down Syndrome Congress

Mass General Brigham researchers find too much sitting hurts the heart

New study shows how salmonella tricks gut defenses to cause infection

Study challenges assumptions about how tuberculosis bacteria grow

NASA Goddard Lidar team receives Center Innovation Award for Advancements

Can AI improve plant-based meats?

How microbes create the most toxic form of mercury

‘Walk this Way’: FSU researchers’ model explains how ants create trails to multiple food sources

A new CNIC study describes a mechanism whereby cells respond to mechanical signals from their surroundings

Study uncovers earliest evidence of humans using fire to shape the landscape of Tasmania

Researchers uncover Achilles heel of antibiotic-resistant bacteria

Scientists uncover earliest evidence of fire use to manage Tasmanian landscape

[Press-News.org] Scientists sequence genome of high-value grape, seek secrets of wine's aroma
Marking 25th year, UNU-BIOLAC also announces brokered breakthrough to diagnose widespread problem of syphilis with a quick, $1 test